TENAX THERAPEUTICS, INC. Cash and Equivalents

Quick Answer

TENAX THERAPEUTICS, INC. reported Cash and Equivalents of $2.12 million for fiscal year 2022.

TENAX THERAPEUTICS, INC. Cash and Equivalents — Annual History

Fiscal Year Cash and Equivalents YoY Change
2022 $2.12M -62.0%
2021 $5.58M -10.7%
2020 $6.25M +27.4%
2019 $4.91M -60.3%
2018 $12.37M +670.6%
2017 $1.60M -83.9%
2016 $10.00M +173.1%
2015 $3.66M -53.8%
2015 $7.93M -86.4%
2014 $58.32M +7343.3%
2013 $783.5K -58.3%
2012 $1.88M +97.5%
2011 $951.9K +50.5%
2010 $632.7K
1967 $0.00

Quarterly Cash and Equivalents

Quarter Ending Cash and Equivalents YoY QoQ
June 30, 2023 $13.39M +85.3% -7.1%
March 31, 2023 $14.41M +402.5% +578.8%
December 31, 2022 $2.12M -62.0% -44.2%
September 30, 2022 $3.81M -54.4% -47.3%
June 30, 2022 $7.23M +332.5% +152.0%
March 31, 2022 $2.87M -18.9% -48.6%
December 31, 2021 $5.58M -10.7% -33.2%
September 30, 2021 $8.35M +1.4% +399.8%
  • TENAX THERAPEUTICS, INC. showed a decrease of -62.0% in Cash and Equivalents compared to the prior fiscal year.
  • The most recent figure is from TENAX THERAPEUTICS, INC.’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 31, 2023.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment